Monopar Therapeutics — Director's Dealing 2022

Feb 5, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2022-02-02

Reporting Person: KLAUSNER ARTHUR J (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-02	Stock Options	$2.80	A	15128	Acquired	2032-02-01	Common Stock (15128)	Direct
2022-02-02	Restricted Stock Units	$0	A	11436	Acquired		Common Stock (11436)	Direct

Footnotes

F1: Options vest 25% quarterly on March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022.

F2: RSUs vest 25% quarterly on March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022.